Drugs / VIP943
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06034275 | Sep 2023 → May 2025 overdue | B-cell acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Vincerx Pharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIP943 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06034275 ↗ |
| Route | Intravenous | “VIP943 will be administered by IV Infusion weekly” NCT06034275 ↗ |